FLT3 and acute myeloid leukemia: Clinical trial results demonstrate efficacy of midostaurin in wt FLT3‐expressing AML.6, 8 Significantly, midostaurin and its major metabolites have been reported to have a number of kinase targets implicated in transformation and chemoresistance.12 Although considerable pre‐clinical and clinical data have been generated showing efficacy of midostaurin against mutant FLT3‐positive AML, comparatively little is known about the effectiveness of midostaurin against AML expressing wt FLT3 and other driver oncogenes.